16.88USD-1.75%Mkt Cap: 593.69M USDP/E: —Last update: 2026-05-26
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap593.69M USD
Enterprise Value298.34M USD
Revenue (TTM)—
Gross Profit-139.61M USD
Net Income (TTM)-163.71M USD
Revenue/Share—
Last Price16.88 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees104
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.28
PEG—
EV/EBITDA-1.66
EV/Revenue—
P/S—
P/B2.27
EPS (TTM)-4.71
EPS (Forward)-3.18
52W Range
14.7917% of range26.80
52W High26.80 USD
52W Low14.79 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-41.80%
ROA-37.05%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-125.81M USD
CapEx (TTM)358.00K USD
FCF Margin—
FCF Yield—
Net Debt-286.46M USD
Net Debt/EBITDA1.59
Balance Sheet
Debt/Equity0.04
Current Ratio8.74
Quick Ratio8.65
Book Value/Sh7.379 USD
Cash/Share8.210 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)39.43 USD
Target Range30.00 USD – 54.00 USD
# Analysts7
Ownership
Shares Out.34.89M
Float31.08M
Insiders6.51%
Institutions39.06%
Short Interest
Short Ratio12.6d
Short % Out.11.60%
Shares Short4.03M
Technical
SMA 5020.16 (-16.3%)
SMA 20020.16 (-16.3%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)454.01K
Avg Vol (10d)408.83K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—